China Tobacco Hong Kong (06055.HK) 2024 Mid-Year Report: Total Revenue Up 12% to 8.7B HKD, NGPs Soar by 28%

Business by 2FIRSTS.ai
Aug.28.2024
China Tobacco Hong Kong (06055.HK) 2024 Mid-Year Report: Total Revenue Up 12% to 8.7B HKD, NGPs Soar by 28%
China Tobacco Hong Kong (06055.HK) revealed its mid-term financial report for 2024 on August 27. Company's total revenue rose 12%.

On August 27th, China Tobacco Hong Kong (06055.HK) released its interim performance report for 2024. During the period, the company's revenue reached 8.704 billion Hong Kong dollars, a 12% increase compared to the previous year; the company's attributable profit to equity holders reached 643 million Hong Kong dollars, a 41% increase year-on-year; and gross profit reached 964 million Hong Kong dollars, a 29% increase year-on-year.

China Tobacco Hong Kong (06055.HK) 2024 Mid-Year Report: Total Revenue Up 12% to 8.7B HKD, NGPs Soar by 28%
Image source: China Tobacco Hong Kong

 

  • The export business of new tobacco products has seen an increase in operating income, reaching 43.5 million Hong Kong dollars, a 28% year-on-year growth, with gross profit increasing by 57%. 
  • Cigarette export business has grown rapidly, with operating income reaching 547.3 million Hong Kong dollars, a 128% year-on-year growth, and gross profit increasing by 223%. 
  • The import and export of tobacco leaf products have seen stable growth, with import business income increasing by 5% year-on-year, and export business operating income increasing by 23% year-on-year. 
  • Operating income from business operations in Brazil has increased by 43% year-on-year, with gross profit decreasing by 8%.

 

The report reveals:

 

The company's growth in the new tobacco product sector is mainly attributed to tapping into key market channels, increasing customer marketing efforts, resulting in increased demand for orders in key markets; as well as continuously expanding their product portfolio, optimizing product pricing strategies, and increasing the proportion of self-operated business.

 

The company stated that the significant growth in cigarette export business was due to the continuous optimization of product portfolio, increased investment in new products, expansion of self-operated business, leading to a substantial increase in revenue and gross profit from cigarette export business. Additionally, foot traffic in duty-free markets has been steadily recovering, leading to improved product turnover compared to the same period last year.

 

Due to seasonal fluctuations in tobacco leaf production and an increase in the selling price of tobacco products, Chinese tobacco company CNTC's tobacco import business in Hong Kong saw a slight growth. The growth in tobacco export business is beneficial for increasing demand in the international market and optimizing pricing strategies.

 

Despite a significant increase in operating income in Brazil, gross profit has actually decreased compared to the same period last year. The company stated that this is due to a significant increase in the proportion of finished cigarette sales with high selling prices but low gross margins, while the proportion of product sales with high gross margins but lower selling prices has decreased.

 

In addition, China Tobacco Hong Kong stated that in the second half of this year, they will continue to enhance the international visibility of new tobacco products, deepen cooperation between production and sales, and comprehensively promote innovation in new tobacco technology and product upgrades.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
Philip Morris Malaysia Again Meets Religious Authority Over Cigarette Alternatives as Perlis Mufti Responds on Halal Criteria
Philip Morris Malaysia Again Meets Religious Authority Over Cigarette Alternatives as Perlis Mufti Responds on Halal Criteria
Philip Morris Malaysia Managing Director Naeem Shahab Khan met Perlis Mufti Mohd Asri Zainul Abidin on September 17 and presented the company's shift from conventional cigarettes toward alternative products. The mufti said a product could be considered halal if it is clean, its side effects are not harmful or can be controlled, and it does not involve excessive waste. His remarks did not mention IQOS or any other specific PMI product and did not amount to a new product-specific religious ruling. It was at least the second publicly reported engagement between Philip Morris Malaysia and a Malaysian religious institution over cigarette alternatives within six months.
Regulations
Sep.18 by 2Firsts Perspectives
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
PMI CEO Attends Opening of IQOS Global Flagship in Tokyo’s Ginza as 1,814 Limited ILUMA i PRIME Sets Launch
IQOS opened its first global flagship, IQOS Flagship Ginza, in Tokyo on September 4, 2026, replacing the former IQOS Store Ginza after nearly a decade of operation. The new location expands conventional product retail into member lounges, digital experiences, art installations and brand programming. IQOS also launched a Ginza-exclusive IQOS ILUMA i PRIME set limited to 1,814 individually numbered units, priced at JPY11,980, or about US$77. PMI Sales Strategy Consultant Yuji M. later said on LinkedIn that more than 500 people had lined up from the night before the opening.
Sep.07
Product | JTI Launches Ploom AURA Teal Electric Pop in South Korea, Its First Dual-Color Edition
Product | JTI Launches Ploom AURA Teal Electric Pop in South Korea, Its First Dual-Color Edition
JTI Korea launched the Ploom AURA Teal Electric Pop limited edition in South Korea on September 1, 2026, marking the first dual-color design in the Ploom AURA range. The device combines a dark green body with teal accents and is accompanied by matching Front Panel, Back Cover and Pocket Bag accessories. The standalone device is priced at KRW 29,000, with three additional device-and-accessory bundles available. The release continues JTI Korea's use of limited colorways and interchangeable accessories to expand the Ploom AURA portfolio without introducing a new hardware platform.
Sep.03
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25